2023 ASCO Annual Meeting: Phase 1 Study of Pritumumab in Brain Cancer
CLICK TO DOWNLOAD PDF
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
NASCENT BIOTECH NEWS
CLICK TO DOWNLOAD PDF
Nascent Biotech, Inc. (NBIO)
JOIN OUR EMAIL NEWSLETTER
Delivering human antibodies for the treatment of cancer